- Home
- SXTP vs FLZH Comparison
SXTP vs FLZH Comparison
Compare SXTP & FLZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.57
N/A
Current Price
$1.71
Company Overview
Basic Information| Metric | SXTP | FLZH |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SXTP | FLZH |
|---|---|---|
| Price | $1.57 | $1.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.10 | N/A |
| AVG Volume (30 Days) | 58.0K | ★ 124.8K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $51.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $1.60 |
| 52 Week High | $8.62 | $2.88 |
Technical Indicators
Market Signals| Indicator | SXTP | FLZH |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 21.18 |
| Support Level | $1.29 | $1.64 |
| Resistance Level | $1.59 | $1.91 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 18.00 | 35.48 |
Price Performance
Historical Comparison SXTP
FLZH
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.